Display options
Cite
Ghadiri F, Sahraian MA, Shaygannejad V, et al. Characteristics of COVID-19 in patients with multiple sclerosis. Mult Scler Relat Disord. 2021;57:103437doi: 10.1016/j.msard.2021.103437.
Ghadiri, F., Sahraian, M. A., Shaygannejad, V., Ashtari, F., Ghalyanchi, H., Baghbanian, S. M., Mojdehipanah, H., Majdi-Nasab, N., Hosseini, S., Poursadeghfard, M., Beladimoghadam, N., Razazian, N., Ayoubi, S., Rezaeimanesh, N., Eskandarieh, S., & Naser Moghadasi, A. (2021). Characteristics of COVID-19 in patients with multiple sclerosis. Multiple sclerosis and related disorders, 57103437. https://doi.org/10.1016/j.msard.2021.103437
Ghadiri, Fereshteh, et al. "Characteristics of COVID-19 in patients with multiple sclerosis." Multiple sclerosis and related disorders vol. 57 (2021): 103437. doi: https://doi.org/10.1016/j.msard.2021.103437
Ghadiri F, Sahraian MA, Shaygannejad V, Ashtari F, Ghalyanchi H, Baghbanian SM, Mojdehipanah H, Majdi-Nasab N, Hosseini S, Poursadeghfard M, Beladimoghadam N, Razazian N, Ayoubi S, Rezaeimanesh N, Eskandarieh S, Naser Moghadasi A. Characteristics of COVID-19 in patients with multiple sclerosis. Mult Scler Relat Disord. 2021 Nov 30;57:103437. doi: 10.1016/j.msard.2021.103437. Epub 2021 Nov 30. PMID: 34896875; PMCID: PMC8629769.
Copy Download .nbib Format: NLM
Share it on

Mult Scler Relat Disord. 2021 Nov 30;57:103437. doi: 10.1016/j.msard.2021.103437. Epub 2021 Nov 30.

Characteristics of COVID-19 in patients with multiple sclerosis.

Multiple sclerosis and related disorders

Fereshteh Ghadiri, Mohammad Ali Sahraian, Vahid Shaygannejad, Fereshteh Ashtari, Hamidreza Ghalyanchi, Seyed Mohammad Baghbanian, Hossein Mojdehipanah, Nastaran Majdi-Nasab, Samaneh Hosseini, Maryam Poursadeghfard, Nahid Beladimoghadam, Nazanin Razazian, Saeideh Ayoubi, Nasim Rezaeimanesh, Sharareh Eskandarieh, Abdorreza Naser Moghadasi

Affiliations

  1. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran.
  2. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
  3. Department of Neurology, Poursina Hospital, Guilan University of Medical Sciences, Rasht, Iran.
  4. Department of Neurology, Booalicina Hospital, Mazandaran University of Medical Sciences, Sari, Iran.
  5. Department of Neurology, Qazvin University of Medical Sciences, Qazvin, Iran.
  6. Musculoskeletal Rehabilitation Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
  7. Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
  8. Department of Neurology, Nemazee Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
  9. Department of Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  10. Department of Neurology, Medicine Faculty, Kermanshah University of Medical Sciences, Kermanshah, Iran.
  11. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: [email protected].
  12. Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: [email protected].

PMID: 34896875 PMCID: PMC8629769 DOI: 10.1016/j.msard.2021.103437

Abstract

BACKGROUND: Regarding the high prevalence of multiple sclerosis (MS) and COVID-19 in Iran, a multicenter study of COVID-19 in Iranian MS patients with is carried out to address the concerns of this population.

METHODS: Data on MS patients with COVID-19 from nine provinces of Iran were entered in a web-based registry system, between July 2020 and March 2021. Among the COVID-19 symptoms, dyspnea, altered mental status, or those resulting in hospital admission were considered severe.

RESULTS: A total of 397 eligible patients were identified. In addition, 310 (78%) were female. The mean age was 36.5 ± 9.5. 294 (74%) patients had relapsing- remitting form. Also, four patients (1%) expired due to COVID-19 infection. The mean duration of admission in hospitalized patients was 9 (± 5.3) days. MRI was performed on 111 (28%) patients after developing COVID-19. MRI changes were observed in 27 (24%) of these cases. MS drug was changed in 26 (6%) patients. Steroid use in the past three months (OR: 2.43, 95% CI: 1.003-5.88) (p value: 0.049) and antiCD20s (OR: 4.03, 95% CI: 2.41-6.68) (p value < 0.001) showed significant association with severe COVID-19 symptoms.

CONCLUSION: The death rate of COVID-19 among MS patients (1%) is lower than the overall death rate of the pandemic in Iran (3%). Those who received steroid in the past three months may be at increased risk of more severe forms of COVID-19. There are still doubts about the effect of anti CD20s on COVID-19 severity.

Copyright © 2021 Elsevier B.V. All rights reserved.

Keywords: COVID-19; Iran; Multiple sclerosis

References

  1. J Neurol. 2020 Dec;267(12):3467-3475 - PubMed
  2. Curr Nutr Rep. 2021 Sep;10(3):200-210 - PubMed
  3. JAMA Neurol. 2021 Jun 1;78(6):699-708 - PubMed
  4. Eur J Neurol. 2021 Nov;28(11):3712-3721 - PubMed
  5. mSystems. 2021 May 4;6(3): - PubMed
  6. BMC Neurol. 2020 May 2;20(1):169 - PubMed
  7. Mult Scler. 2018 Feb;24(2):92-95 - PubMed
  8. Public Health. 2019 Oct;175:138-144 - PubMed
  9. Basic Clin Neurosci. 2020 Mar-Apr;11(2):201-206 - PubMed
  10. JAMA. 2020 May 12;323(18):1824-1836 - PubMed
  11. Ann Neurol. 2021 Apr;89(4):780-789 - PubMed
  12. JAMA Neurol. 2020 Feb 1;77(2):184-191 - PubMed
  13. JAMA Neurol. 2020 Sep 1;77(9):1079-1088 - PubMed
  14. BMJ. 2020 May 14;369:m1849 - PubMed
  15. MMWR Morb Mortal Wkly Rep. 2020 Jul 03;69(26):841-846 - PubMed
  16. Ann Clin Transl Neurol. 2021 Aug;8(8):1738-1744 - PubMed
  17. Mult Scler Relat Disord. 2019 Aug;33:158-161 - PubMed

Publication Types